Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$10.32 -0.9%	$8.79	$2.99 ▼ $10.87	$1.57B	1.8	1.57 million shs	979,158 shs
CNTA Centessa Pharmaceuticals	$12.38 +2.8%	$12.58	$8.46 ▼ $19.09	$1.65B	1.48	703,255 shs	1.04 million shs
ETNB 89bio	$10.41 +8.2%	$8.06	$4.16 ▼ $11.84	$1.40B	1.3	1.50 million shs	3.93 million shs
KMDA Kamada	$6.88 -0.9%	$6.65	$4.74 ▼ $9.16	$395.63M	0.94	93,860 shs	109,223 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	0.00%	+2.28%	+15.82%	+41.76%	+198.27%
CNTA Centessa Pharmaceuticals	0.00%	+3.86%	-1.67%	-27.77%	+27.63%
ETNB 89bio	0.00%	+1.56%	+36.26%	+22.90%	+10.04%
KMDA Kamada	0.00%	+0.44%	+0.29%	-4.18%	+34.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	2.5465 of 5 stars	1.4	1.0	4.2	2.3	2.5	0.6
CNTA Centessa Pharmaceuticals	3.6313 of 5 stars	4.5	2.0	0.0	2.6	3.3	0.6
ETNB 89bio	2.4793 of 5 stars	3.5	3.0	0.0	2.8	0.8	0.6
KMDA Kamada	3.8752 of 5 stars	3.4	3.0	0.0	2.9	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.83	Moderate Buy	$9.83	-4.72% Downside
CNTA Centessa Pharmaceuticals	3.00	Buy	$27.89	125.27% Upside
ETNB 89bio	3.00	Buy	$26.43	153.88% Upside
KMDA Kamada	2.75	Moderate Buy	$14.67	113.18% Upside

Current Analyst Ratings Breakdown

Latest KMDA, CNTA, ADPT, and ETNB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	ETNB 89bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
5/28/2025	CNTA Centessa Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$35.00
5/24/2025	ETNB 89bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
5/15/2025	KMDA Kamada	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
5/10/2025	ETNB 89bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
5/8/2025	CNTA Centessa Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform ➝ Outperform	$6.00
5/8/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
5/8/2025	KMDA Kamada	Sidoti Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
5/6/2025	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$11.00 ➝ $13.00
5/5/2025	ADPT Adaptive Biotechnologies	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$7.00 ➝ $9.00
5/2/2025	ADPT Adaptive Biotechnologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$189.53M	8.27	N/A	N/A	$1.37 per share	7.53
CNTA Centessa Pharmaceuticals	$15M	110.23	N/A	N/A	$2.42 per share	5.12
ETNB 89bio	N/A	N/A	N/A	N/A	$5.75 per share	N/A
KMDA Kamada	$167.24M	2.37	$0.38 per share	17.90	$4.25 per share	1.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.96	N/A	N/A	N/A	-89.12%	-64.65%	-26.45%	7/30/2025 (Estimated)
CNTA Centessa Pharmaceuticals	-$151.09M	-$1.81	N/A	N/A	N/A	N/A	-52.13%	-38.01%	8/12/2025 (Estimated)
ETNB 89bio	-$142.19M	-$3.38	N/A	N/A	N/A	N/A	-59.58%	-52.21%	8/4/2025 (Estimated)
KMDA Kamada	$8.28M	$0.29	24.57	21.50	0.97	9.92%	6.30%	4.49%	8/13/2025 (Estimated)

Latest KMDA, CNTA, ADPT, and ETNB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	KMDA Kamada	$0.07	$0.07	N/A	$0.07	$154.06 million	$44.02 million
5/12/2025	Q1 2025	CNTA Centessa Pharmaceuticals	-$0.35	-$0.20	+$0.15	-$0.20	N/A	N/A
5/1/2025	Q1 2025	ADPT Adaptive Biotechnologies	-$0.28	-$0.20	+$0.08	-$0.20	$42.13 million	$52.44 million
5/1/2025	Q1 2025	ETNB 89bio	-$0.50	-$0.49	+$0.01	-$0.49	N/A	N/A
3/24/2025	Q4 2024	CNTA Centessa Pharmaceuticals	-$0.38	-$0.34	+$0.04	-$0.84	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ETNB 89bio	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.89	2.81
CNTA Centessa Pharmaceuticals	0.15	21.52	21.52
ETNB 89bio	0.09	11.66	11.66
KMDA Kamada	N/A	4.84	2.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
CNTA Centessa Pharmaceuticals	82.01%
ETNB 89bio	N/A
KMDA Kamada	20.38%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
CNTA Centessa Pharmaceuticals	7.09%
ETNB 89bio	2.60%
KMDA Kamada	36.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	151.92 million	138.43 million	Optionable
CNTA Centessa Pharmaceuticals	200	133.56 million	116.56 million	Optionable
ETNB 89bio	40	145.98 million	103.15 million	Optionable
KMDA Kamada	360	57.51 million	36.73 million	Optionable

KMDA, CNTA, ADPT, and ETNB Headlines

Recent News About These Companies

Daichi Kamada Highlights Quality Gap Between Indonesian and Australian National Teams

June 12 at 11:52 AM | en.tempo.co

Kamada nets brace in Japan rout as South Korea put four past Kuwait

June 10, 2025 | beinsports.com

Kamada hits double as Japan thrash Indonesia 6-0

June 10, 2025 | msn.com

Implied Volatility Surging for Kamada Stock Options

June 10, 2025 | msn.com

Football: Daichi Kamada, Takefusa Kubo spur Japan to big win over Indonesia

June 10, 2025 | mainichi.jp

Millennium Management LLC Sells 36,872 Shares of Kamada Ltd. (NASDAQ:KMDA)

June 3, 2025 | marketbeat.com

Wall Street Analysts Think Kamada (KMDA) Could Surge 106.86%: Read This Before Placing a Bet

June 2, 2025 | zacks.com

Are Investors Undervaluing Kamada (KMDA) Right Now?

June 2, 2025 | zacks.com

KMDA vs. CSLLY: Which Stock Should Value Investors Buy Now?

May 28, 2025 | zacks.com

Kamada (NASDAQ:KMDA) Stock Crosses Below 200 Day Moving Average - What's Next?

May 28, 2025 | marketbeat.com

HC Wainwright Issues Optimistic Outlook for Kamada Earnings

May 20, 2025 | marketbeat.com

Is Kamada (KMDA) Stock Undervalued Right Now?

May 16, 2025 | msn.com

Wall Street Analysts Believe Kamada (KMDA) Could Rally 106.56%: Here's is How to Trade

May 16, 2025 | msn.com

Compared to Estimates, Kamada (KMDA) Q1 Earnings: A Look at Key Metrics

May 15, 2025 | msn.com

Kamada Ltd (KMDA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion

May 15, 2025 | finance.yahoo.com

Kamada Ltd. (NASDAQ:KMDA) Q1 2025 Earnings Call Transcript

May 15, 2025 | msn.com

Kamada Ltd. (KMDA) Q1 2025 Earnings Call Transcript

May 14, 2025 | seekingalpha.com

Kamada (KMDA) Q1 Earnings Match Estimates

May 14, 2025 | zacks.com

Kamada Reports Strong Q1 2025 Financial Results and Expands Plasma Operations

May 14, 2025 | tipranks.com

Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability

May 14, 2025 | globenewswire.com

Earnings Preview For Kamada

May 14, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KMDA, CNTA, ADPT, and ETNB Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$10.32 -0.09 (-0.86%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$10.32 +0.00 (+0.05%)

As of 06/13/2025 07:48 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Centessa Pharmaceuticals NASDAQ:CNTA

$12.38 +0.34 (+2.82%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$12.36 -0.03 (-0.20%)

As of 06/13/2025 06:59 PM Eastern

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

89bio NASDAQ:ETNB

$10.41 +0.79 (+8.21%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$9.85 -0.56 (-5.42%)

As of 06/13/2025 06:03 PM Eastern

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Kamada NASDAQ:KMDA

$6.88 -0.06 (-0.86%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$6.94 +0.05 (+0.80%)

As of 06/13/2025 04:25 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time